Literature DB >> 25413611

Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.

Matthew R Sullivan1,2, Alexey V Danilov1,2, Frederick Lansigan1,2, Nancy M Dunbar1,3.   

Abstract

Drug associated thrombotic microangiopathy (TMA) is a rare event causing thrombocytopenia, microangiopathic anemia, renal failure, and neurologic abnormalities. Here, we present a case of TMA that occurred during the first cycle of treatment with carfilzomib for relapsed multiple myeloma.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  carfilzomib; multiple myeloma; plasma exchange; thrombotic microangiopathy

Mesh：

Substances：

Year:  2014        PMID： 25413611     DOI： 10.1002/jca.21371

Source DB:  PubMed          Journal:  J Clin Apher        ISSN： 0733-2459            Impact factor:   2.821


  10 in total

1.  Carfilzomib-induced nephrotoxcity.

Authors:  Kenar D Jhaveri; Rimda Wanchoo
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

2.  The Authors Reply.

Authors:  Mark A Perazella; Hassan Izzedine
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

3.  Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.

Authors:  Eleni Gavriilaki; Dimitra Dalampira; Foteini Theodorakakou; Christine-Ivy Liacos; Nikolaos Kanellias; Evangelos Eleutherakis-Papaiakovou; Evangelos Terpos; Maria Gavriatopoulou; Evgenia Verrou; Theodora Triantafyllou; Aggeliki Sevastoudi; Evaggelia-Evdoxia Koravou; Tasoula Touloumenidou; Christos Varelas; Apostolia Papalexandri; Ioanna Sakellari; Meletios A Dimopoulos; Efstathios Kastritis; Eirini Katodritou
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 4.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

5.  Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib.

Authors:  Vladimir Liberman; Vivette D D'Agati; Naveed N Masani; James Drakakis; Joseph Mattana
Journal:  Kidney Int Rep       Date:  2016-06-23

6.  Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Authors:  Clarissa A Cassol; Michael P A Williams; Tiffany N Caza; Sophia Rodriguez
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.

Authors:  Panagiotis Efentakis; Hendrik Doerschmann; Claudius Witzler; Svenja Siemer; Panagiota-Efstathia Nikolaou; Efstathios Kastritis; Roland Stauber; Meletios Athanasios Dimopoulos; Philip Wenzel; Ioanna Andreadou; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

8.  Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis.

Authors:  Odianosen Eigbire-Molen; Daniela Hermelin; Douglas Blackall
Journal:  J Med Cases       Date:  2022-06-11

9.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

10.  Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma.

Authors:  Jan Van Keer; Michel Delforge; Daan Dierickx; Kathelijne Peerlinck; Evelyne Lerut; Ben Sprangers
Journal:  Case Rep Hematol       Date:  2016-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.